Medtronic Shares Fall As Blood Pressure Reduction Device Fails On Primary Goal


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


  • Medtronic plc (NYSE:MDTannounced the six-month results from the full cohort of the SPYRAL HTN-ON MED trial. 
  • Subjects in the Symplicity Spyral Renal Denervation (RDN) System had a statistically significant and clinically meaningful reduction in office-based systolic blood pressure (OSBP), a key secondary endpoint, compared to the sham control group. 
  • However, in the primary endpoint, RDN did not demonstrate a statistically significant reduction in 24-hour ambulatory systolic blood pressure (ABPM).
  • Medtronic’s device cut systolic blood pressure by 6.5 points vs. 4.5 in the sham procedure group. 
  • Renal denervation reduced this measure of blood pressure by 9.9 points versus a 4.9-point reduction for patients in the sham procedure, a statistically significant improvement.
  • The company blamed the increased medications in the sham control group and the potential COVID-19 impacts on the clinical trial environment. 
  • The study met its primary safety endpoint, with a low incidence of procedure-related and clinical adverse events.
  • Despite falling short of the study’s main efficacy goal, Medtronic said it had completed its application to the FDA for approval of the device.
  • Medtronic’s product is approved for commercial use in more than 60 countries but not in the U.S., Japan, and Canada.
  • Wall Street Journal writes that if the FDA approves the device, it could offer a new, nonmedication treatment option for people with high blood pressure despite drug treatment. It could also be a big-selling product for Medtronic.
  • Price Action: MDT shares are down 5.31% at $81 during the premarket session on the last check Tuesday.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Large CapNewsHealth CareFDAPre-Market OutlookMoversTrading IdeasGeneralBriefswhy it's moving